Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise’s muscular dystrophy business headed by sevasemten.

The NHS digital single patient record (SPR) could result in 20,000 fewer A&E visits in England per year and save £20m a year, says the

Trials of AstraZeneca’s anselamimab and Regeneron’s Lynozyfic could deliver much-needed new therapeutic options for rare disease AL amyloidosis.

Millions of women with a breast cancer diagnosis could safely avoid chemotherapy that would not be effective, thanks to a genomics test.

ViiV Healthcare is teaming up with TV personality, HIV and LGBTQ advocate Michelle Visage to help broaden awareness about new, longer-acting medicines that can significantly